All terms
Market SegmentsStrategic Landscape
Urology Devices
Devices for diagnosis and treatment of disorders of the urinary tract and male reproductive system — including BPH therapy, stone management, and continence devices.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026
Definition
The urology MedTech segment includes BPH (benign prostatic hyperplasia) therapies (laser enucleation, water-vapor, prostatic urethral lift), kidney-stone management (lithotripsy, ureteroscopes, baskets), incontinence and pelvic-floor devices (slings, artificial urinary sphincters, sacral neuromodulation), urodynamics systems, and erectile prosthetics. Class spans Class I catheters through Class III implants. What the regulation says
Most urology devices are regulated under 21 CFR 876. Sacral neuromodulators are PMA Class III. Energy-based BPH devices typically clear via 510(k) with comparative clinical data in expanded submissions.
What this means in practice
Reimbursement turns on AUA guideline alignment and CMS coverage for the specific procedure code. Outpatient migration (ASC site-of-service shift) is a major economic driver. Common pitfalls
- •Assuming a slight energy-modality change qualifies as substantially equivalent without comparative clinical data.
- •Overlooking the AUA practice guidelines that drive payer coverage decisions.
Primary references
3 sourcesLink health: 3 verified· last checked 2026-05-09
eCFR·1AUA·1AdvaMed·1
- 1
21 CFR 876 Gastroenterology-Urology DevicesVerifiedeCFRecfr.gov
- 2
American Urological Association GuidelinesVerifiedAUAauanet.org
- 3
AdvaMed - Industry ReportsVerifiedAdvaMedadvamed.org
Inline markers like [1] jump to the matching reference above.